SEPIA ACS-TIMI 42
SEPIA-ACS-TIMI 42 evaluated the efficacy and safety of otamixaban, a direct factor Xa inhibitor, in patients with non-ST-elevation acute coronary syndrome.
Key Study Publications
Sabatine, M. S., Antman, E. M., Widimsky, P., Ebrahim, I. O., Kiss, R. G., Saaiman, A., Polasek, R., Contant, C. F., McCabe, C. H., Braunwald, E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet. 2009;374(9692):787-95. Abstract